Capricor Therapeutics宣布，美国食品药品监督管理局（FDA）的咨询委员会将召开会议，以审查其候选药物Deramiocel用于治疗杜氏肌营养不良症（DMD）的生物制剂许可申请（BLA）。
Capricor Therapeutics宣布，美国食品药品监督管理局（FDA）的咨询委员会将召开会议，以审查其候选药物Deramiocel用于治疗杜氏肌营养不良症（DMD）的生物制剂许可申请（BLA）。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.